Zobrazeno 1 - 10
of 23
pro vyhledávání: '"C D, Sjöström"'
Autor:
C. W. le Roux, C D Sjöström, Kajsa Sjöholm, Magdalena Taube, Lena M. S. Carlsson, A. Shulman, P-A Svensson, Johanna C. Andersson-Assarsson, Markku Peltonen, Peter Jacobson
Publikováno v:
International journal of obesity (2005)
Bariatric surgery reduces incidence of albuminuria and end-stage renal disease in patients with obesity. Effects of bariatric surgery on long-term remission and progression of pre-existing obesity-related renal damage are mainly unexplored. Here we i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54598f7e755690c499d3a9442b37e82c
http://europepmc.org/articles/PMC7914157
http://europepmc.org/articles/PMC7914157
Incidence of End-Stage Renal Disease Following Bariatric Surgery in the Swedish Obese Subjects Study
Autor:
Lena M. S. Carlsson, C. W. le Roux, Markku Peltonen, Johanna C. Andersson-Assarsson, Per-Arne Svensson, Kajsa Sjöholm, A. Shulman, C D Sjöström, Magdalena Taube
Publikováno v:
International journal of obesity (2005)
Background Obesity is a major public health problem leading to co-morbidities such as diabetes, hypertension and kidney failure. Bariatric surgery results in pronounced and maintained weight loss and prevention of obesity-related diseases and their c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc5161411f92f6184d330616573dcc9e
http://europepmc.org/articles/PMC6019553
http://europepmc.org/articles/PMC6019553
Autor:
David C. Wheeler, Ricardo Correa-Rotter, Fan Fan Hou, Niels Jongs, Bergur V. Stefánsson, John J.V. McMurray, H. Lambers Heerspink, R D Toto, AM Langkilde, Priya Vart, C. D. Sjöström, Glenn M. Chertow, Peter Rossing, José Luis Górriz
Publikováno v:
Kidney International Reports, Vol 6, Iss 4, Pp S361-S362 (2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc68886349bae45ab483801ca5175ebf
https://doi.org/10.1016/j.ekir.2021.03.869
https://doi.org/10.1016/j.ekir.2021.03.869
Autor:
Ricardo Correa-Rotter, AM Langkilde, R D Toto, Niels Jongs, C. D. Sjöström, Glenn M. Chertow, Priya Vart, H. Lambers Heerspink, J Jv McMurray, Fan Fan Hou, David C. Wheeler, Bergur V. Stefánsson, Kausik Umanath, Peter Rossing, Roberto Pecoits-Filho
Publikováno v:
Kidney International Reports, Vol 6, Iss 4, Pp S362-(2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::650a4e841b156c329e7cbe93daf85e30
https://doi.org/10.1016/j.ekir.2021.03.870
https://doi.org/10.1016/j.ekir.2021.03.870
Publikováno v:
Diabetes, Obesity & Metabolism
Diabetes obesity & metabolism, 18(6), 590-597. Wiley
Diabetes obesity & metabolism, 18(6), 590-597. Wiley
Aims: To characterize the effect of dapagliflozin on albuminuria and estimated glomerular filtration rate (eGFR) and to determine whether effects on albuminuria were mediated through changes in glycated haemoblogin (HbA1c), systolic blood pressure (S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4c71aee53c1d21a28e80e6c929cce2e
https://hdl.handle.net/11370/cd565ae2-797d-45a6-b14c-740c083c4d35
https://hdl.handle.net/11370/cd565ae2-797d-45a6-b14c-740c083c4d35
Publikováno v:
Diabetes, Obesity and Metabolism. 17:809-812
The aim of this study was to investigate the associations between dapagliflozin-mediated reductions in body weight and reductions in glycated haemoglobin (HbA1c) and blood pressure. Data were pooled from seven studies evaluating dapagliflozin 10 mg a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f99ddeb704319ce5bbed7c62871f596f
https://doi.org/10.1111/dom.12500
https://doi.org/10.1111/dom.12500
Publikováno v:
Diabetes, Obesity and Metabolism. 16:645-650
Aims This study evaluated change in health-related quality of life (HRQOL) associated with ongoing weight change among patients with type 2 diabetes mellitus (T2DM) treated with dapagliflozin, a highly selective sodium-glucose cotransporter 2 (SGLT2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6dae92d3c345c9909cb60d6682a1bd4
https://doi.org/10.1111/dom.12263
https://doi.org/10.1111/dom.12263
Autor:
Lars Johansson, Shamik Parikh, C. D. Sjöström, John P.H. Wilding, Anna Maria Langkilde, Östen Ljunggren, Jennifer Sugg, Jan Bolinder
Publikováno v:
Diabetes, Obesity and Metabolism. 16:159-169
Aims Dapagliflozin, a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduces hyperglycaemia and weight in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion. Long-term glycaemic control, body
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abc3ddb684f463d4c0f3e28cd01a019d
https://doi.org/10.1111/dom.12189
https://doi.org/10.1111/dom.12189
Autor:
C. D. Sjöström, Shamik Parikh, Jan Bolinder, Anna Maria Langkilde, Östen Ljunggren, Lars Johansson, John P.H. Wilding, Jennifer Sugg
Publikováno v:
Diabetes, Obesity and Metabolism. 14:990-999
Aims Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces hyperglycaemia in patients with type 2 diabetes (T2DM) by increasing urinary glucose excretion. Owing to its mechanism of action, dapagliflozin could potentiall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a58af697fde1281541cb61a330fcf219
https://doi.org/10.1111/j.1463-1326.2012.01630.x
https://doi.org/10.1111/j.1463-1326.2012.01630.x
Publikováno v:
International Journal of Obesity. 35:1413-1420
Objective: Many short-term studies indicate that 5% weight loss in the obese is enough to induce significant improvements of cardiovascular risk factors. However, it is not known what degree of weight loss is required to improve risk factors over a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2fe790612912b2813999372a6887ca1
https://doi.org/10.1038/ijo.2010.282
https://doi.org/10.1038/ijo.2010.282